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Introduction
Today, obesity, as one of the consequences of the modern lifestyle (increased food intake and a sedentary lifestyle), has become an international concern (1) . Inflammation caused by adipose tissue, which increases with obesity, increases the risk of incidence of many diseases such as fatty liver and metabolic syndrome (2) . Metabolic syndrome consists of a series of metabolic abnormalities such as central obesity, insulin resistance, hyperglycemia, hypertension, and dyslipidemia which increase the risk of diabetes and cardiovascular diseases (CVD) (3, 4) . Regardless of the difference in the prevalence of this disease in different areas due to factors such * as race and climate, it has been reported that one-fourth of the world population suffer from metabolic syndrome (5, 6) .
According to the World Health Organization (WHO) reports, metabolic syndrome is the new pandemic of the 21 st century and it is anticipated that approximately half of the world population will be suffering from this disease in the span of the next 20 years. In Iran, the incidence of this disease has had an increasing trend; its prevalence increased from 30.1% in 2002 to 34.7% in 2009 (7) . Adipokines (e.g., Leptin, adiponectin, and chemerin) are polypeptide produced and secreted by adipose tissue and are associated with functions such as insulin resistance, inflammation, and blood pressure regulation (7, 8) . Chemerin, also known as tazarotene-induced gene 2 protein (TIG2) and retinoic acid receptor responder protein 2 (RARRES2), is an adipokine. This adipokine plays a role in different functions through adipocyte and immune cell surface receptors. Chemerin acts as a chemotactic factor, and using its receptors on the surface of immune cells, causes the movement of these cells toward adipose tissue, and thus, inflammation. It also has a role in the differentiation, homeostasis, and enlargement of fat cells. In addition, it affects the expression of genes such as glucose transporter type 4 (GLUT4). Chemerin is a chemical absorption protein which regulates the activity of dendritic cells (DCs) and macrophages through the G protein-coupled receptor of CMKL1. Chemerin is secreted in an inactive form and as prochemerin, and is activated through connection with C-terminal domain and by inflammation and coagulation serine proteases (4, 9, 10 (12) . Elsebai et al., in their study on patients with type 2 diabetes, reported that serum chemerin and beta-2 microglubulin levels in these patients were related to incidence of diabetic nephropathy (13) . They concluded that adipokine and beta-2 microglublin can be predictive markers for incidence of nephropathy among individuals with diabetes (13). Aksan et al. showed that serum chemerin level was higher and was related with increased risk of CAD in individuals with metabolic syndrome and coronary artery disease (CAD) compared to individuals with metabolic syndrome alone (14) . The present study was conducted with the aim of determining serum chemerin level in individuals with metabolic syndrome in comparison to healthy individuals in Rafsanjan, Iran.
Material and Methods
The statistical population of the present descriptive study consisted of individuals with metabolic syndrome referring to physicians in Rafsanjan in 2016. Their condition was affirmed through clinical examination by a specialist and measurement of metabolic syndrome indices (waist circumference, systolic and diastolic blood pressure, triglyceride, fasting glucose level, and HDL). Healthy individuals were selected from among students and personnel of JOHE, Winter 2016; 5 (1)
Rafsanjan University of Medical Sciences through convenience sampling after referring to the laboratory of the School of Medicine and based on the results of experiments and a physician's diagnosis. These individuals were entered into the study after signing a consent form. The number of participants and sample volume of each group were calculated based on the study by Jialal et al. (11) and using the following equation. The number of 22 participants per group was determined; however, due to possibility of sample loss, a greater number of individuals were entered into the study.
In the above equation:
Based on this equation, the standard deviation of serum chemerin level in individuals with metabolic syndrome (σ 2 ) was determined as 53 ng/ml, and standard deviation of serum chemerin level in individuals without metabolic syndrome (K) as 1. Moreover, an equal sample volume was determined for the two groups (∆ = 50 ng/ml). The minimum difference in mean serum chemerin level in the two groups which was clinically significant was 22 (n Case = n Control ≈ 22). The exclusion criteria consisted of presence of CVD, acute pulmonary disease, hepatitis B and C, Cushing's syndrome, polycystic ovary syndrome (PCOS), and HIV/AIDS, and use of lipid-lowering drugs, glucocorticoids (GCs), and antipsychotics (15, 16 mg/dl The control group, who were matched in terms of age and gender with the metabolic syndrome group, did not have metabolic syndrome based on the NCEP/ATP III, or any of the illnesses listed in the exclusions criteria based on a physician's approval. First, written informed consents were obtained from all participants. Then, their name, surname, age, and gender were recorder. The factors of height, weight, waist circumference, hip circumference, and systolic and diastolic blood pressure were measured by a physician. After 12 hours of fasting, 10 ml blood samples were obtained from the participants and placed in a centrifuge (3000 rpm) for 5-10 minutes in order to separate serum from coagulated blood. Then, the transparent liquid on the surface was removed using a pipette, and placed in microtubes and stored in -20 °C for further examinations (4, 8, 11) . Assessment of biochemical factors: Lipid factors of HDL, LDL, triglyceride, and blood sugar were measured using the BT4500 (Biotechnica, Italy). Assessment of serum chemerin and insulin levels: ELISA kits were used to measure serum chemerin (Zellbio, Germany) and insulin levels (Monobind, USA). Assessment of insulin resistance index: This index was calculated using the relevant equation (18) . 
Results
The study participants consisted of 31 individuals with metabolic syndrome (11 men and 20 women) with mean age of 42.10 ± 12.06 years and 25 controls (14 men and 11 women) with mean age of 37.52 ± 8.96 years. Statistical tests showed no significant difference between mean age of the two groups (P=0.109). Furthermore, chi-square test did not show a significant difference in the gender prevalence distribution of the two groups (P = 0.125). The results of statistical tests are presented in table 1. Based on the results, serum chemerin level was significantly higher in the metabolic syndrome group compared to the control group (P = 0.009). Moreover, mean BMI (P < 0.001), waist circumference (P < 0.001), systolic blood pressure (P = 0.001), diastolic blood pressure (P< 0.001), insulin resistance (P = 0.005), and triglyceride (P < 0.001) was significantly higher in the metabolic syndrome group compared to the control group. However, mean HDL was significantly higher in the control group compared to the patient group (P = 0.007). 
Discussion
Adipokines are polypeptides produced and secreted by adipose tissue and are associated with functions such as insulin resistance, inflammation, and blood pressure regulation (7, 8) . Some human subject studies have reported a relationship between chemerin and metabolic syndrome, obesity, insulin resistance, and inflammation (4). However, some other studies have dismissed the presence of this relationship (19) . Thus, the aim of the present study was the determination of serum chemerin level and its relationship with obesity and insulin resistance in individuals with metabolic syndrome in Rafsanjan.
The present study was conducted on 31 individuals with metabolic syndrome and 25 healthy individuals (control group). The two groups did not differ significantly in terms of age and gender. BMI, waist circumference, systolic and diastolic blood pressure, insulin resistance index, serum insulin and triglyceride levels, and fasting serum glucose level were significantly higher in the metabolic syndrome group compared to the control group. Nevertheless, HDL was higher in the control group in comparison with the patient group. There was no significant difference between the groups in terms of LDL and mean height. Data analysis showed that serum chemerin level was significantly higher in the metabolic syndrome group compared with the control group. These findings are consistent with the results of many previous studies which have reported higher serum chemerin levels in individuals with metabolic syndrome in comparison to a control group (11, 20, 21 (19) . However, they found that it had an inverse relationship with adiponectin and acute-phase proteins, and no relationship with pantraksin enzyme 3, which is an anti-inflammatory agent (19) . Obesity is one of the most important outcomes of the modern lifestyle and increases the risk of many diseases (17) . There are many markers for obesity such as BMI and waist circumference. Obesity is accompanied with increased body fat, and in humans, this adipokine is produced by immune cells and adipose tissues; thus, increased cell count and adipose tissue results in an increase in the production of this adipokine (22) . Some studies have suggested that chemerin is involved in increased insulin resistance in individuals with metabolic syndrome (4, 11) . Nevertheless, no relationship was observed between chemerin level and insulin resistance in these individuals in the present study. The lack of relationship between serum chemerin level and insulin resistance may be due to the presence of different hormones which play a role in insulin resistance. The insulin resistance effect of chemerin is insignificant in comparison to these hormones (15) . The present results suggest that no significant relationship exists between serum chemerin level and triglyceride, LDL, and HDL. This finding is not in agreement with the results of some previous studies in this field (11, 20, 21) . Based on the results of these studies, chemerin has an important role in increased LDL and HDL; this adipokine affects the hepatic cells and increases the level of VLDL which is a precursor of LDL (16) .
Conclusion
Based on the results of the present study and previous studies, serum chemerin level increases in individuals with metabolic syndrome. Therefore, changes in serum chemerin level can be used as a criterion for diagnosis and confirmation of metabolic syndrome, and the assessment of this adipokine can be effective in the determination of appropriate treatment methods.
